– USA, CA – Curate Biosciences, a key enabling technology company for cell therapy manufacturing, today announced the appointment of David Backer to its Board of Directors as the next CEO, bringing decades of cell and gene therapy experience to the company as it looks to accelerate the production of life-saving medicines and change health outcomes for patients with intractable diseases.
“David’s commercial experience and alignment with our vision is the perfect fit for us as Curate goes to market. His deep knowledge of the cell and gene therapy space will help us position our game-changing technology to help advance an industry with so much potential to help the patients most in need,” said Founder and Chairman, Mike Grisham.
Founding CEO Mike Grisham will assume the responsibility of Chairman of the Board of Directors.
About David M. Backer
David Backer most recently served as CCO at Oxford Biomedica, and before that, was SVP of Commercial Development at cell and gene therapy-enabling tech company ElevateBio. He also founded and led the successful sale of Molecular Medicine BioServices to Sigma-Aldrich’s SAFC division, leading to an extensive career at Sigma-Aldrich SAFC and MilliporeSigma. He completed his tenure at MilliporeSigma as Head of Commercial Development for Gene Editing and Novel Modalities.
“I’m delighted to join Curate at this pivotal moment and help capitalize on the great work this team has done to develop a first-in-class technology,” said David Backer. “CAR-T cell therapies have been curative for intractable diseases like cancer, and many more cell therapies are in development for patients. What drew me to Curate is a shared vision of enabling companies to produce improved therapies cost-effectively for more patients.”
About Curate Biosciences
Curate Biosciences is a life science company located in Carlsbad, CA, that has developed what standard cell processing technologies have failed to provide: the best quality starting material to reduce the total vein-to-vein cost dramatically. Curate Biosciences advances its platform technology – The Curate Cell Processing System – to allow a faster path to a cleaner and larger quantities of starting cells, one of the significant bottlenecks in gene and cell therapies. The Curate Cell Processing System isolates leukocytes using Deterministic Cell Separation, an advanced, high-speed microfluidic technology that gently separates cells based on size. Optimized for processing apheresis and cell culture samples, the Curate platform obtains larger quantities of healthier leukocytes compared to other separation technologies.
For more information: https://www.curatebio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
